Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

Gilead will pay LEO Pharma $250 million upfront under the arrangement; further milestone payments may boost the total to $1.7 billion. While LEO Pharma maintains worldwide rights to topical ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

For its money, Gilead gets hold of Leo’s oral STAT6 small-molecule inhibitors and targeted protein degraders. The Big Pharma will take the lead on the oral programs, while Leo will focus on ...